Asia Pacific Coronary and Peripheral Stents Market Outlook (2022-2033)

The Asia Pacific coronary and peripheral stents market size is expected to reach US$ 4,555.2 million by 2033 from US$ 1,871.0 million in 2024. The market is estimated to record a CAGR of 10.6% from 2025 to 2033.

Executive Summary and Asia Pacific Coronary and Peripheral Stents Market Analysis:

The Asia Pacific coronary and peripheral stents market is recognized as the fastest growing region worldwide, propelled by rising cardiovascular disease prevalence, expanding healthcare infrastructure, and increasing adoption of minimally invasive procedures. China dominates the regional landscape, both in scale and growth, due to its vast patient population, strong government support, and robust domestic manufacturing ecosystem. Across Asia Pacific, urbanization and lifestyle changes have heightened the burden of coronary artery disease and peripheral artery disease, creating sustained demand for advanced stent technologies such as drug‑eluting and bioresorbable stents. Private hospitals and public health initiatives are accelerating access, while physician training programs enhance procedural quality. However, challenges remain in the form of fragmented reimbursement systems and regulatory hurdles across diverse markets, which can slow uniform adoption. Despite these restraints, Asia Pacific’s dynamic mix of mature and emerging economies ensures rapid expansion, with China setting the benchmark for innovation, affordability, and procedural volumes.

Asia Pacific Coronary and Peripheral Stents Market Segmentation Analysis

Key segments that contributed to the derivation of the coronary and peripheral stents market analysis are product type, material type, application and end user.

• By product type, the coronary and peripheral stents market is segmented into bare-metal stents, drug-eluting stents, bioresorbable vascular scaffolds, and others. The drug-eluting stents segment dominated the market in 2024. Superior efficacy in reducing restenosis, longer-term patient outcomes, and widespread physician preference drove adoption, making them the most trusted choice compared to bare-metal or bioresorbable alternatives.
• By material type, the coronary and peripheral stents market is segmented into metal, polymer, and hybrid. The metal segment dominated the market in 2024. High durability, proven biocompatibility, cost-effectiveness, and established clinical success ensured dominance, as polymer and hybrid options remain limited in availability, scalability, and long-term performance validation.
• By application, the coronary and peripheral stents market is segmented into coronary artery disease and peripheral artery disease. The coronary artery disease segment dominated the market in 2024. Higher global prevalence, significant clinical burden, and greater demand for interventional procedures positioned coronary stents as the leading application, overshadowing peripheral artery disease interventions in overall market share.
• By end user, the market is segmented into hospitals, ambulatory surgical centers, cardiac catheterization labs, and specialty clinics. The hospitals segment held the largest share of the market in 2024. Comprehensive infrastructure, advanced catheterization facilities, skilled specialists, and ability to handle complex cases ensured hospitals remained the primary setting for stent implantation, surpassing smaller clinics and ambulatory centers.

Asia Pacific Coronary and Peripheral Stents Market Outlook

The Asia Pacific market is evolving rapidly, with coronary drug‑eluting stents and nitinol peripheral stents gaining prominence across hospitals and specialty clinics. The region’s growth is underpinned by rising demand for minimally invasive interventions, supported by expanding catheterization labs and improved physician expertise. A key driver is the rapid healthcare infrastructure development, particularly in China, India, and Southeast Asia, where governments and private investors are building new hospitals and upgrading existing facilities. This infrastructure expansion directly increases stent utilization by enabling more procedures, fostering physician familiarity, and supporting procurement pathways that favor technologically advanced devices. As hospitals modernize, partnerships with global manufacturers and domestic suppliers ensure access to a wide range of stent technologies, while training programs strengthen clinical adoption. This infrastructure-led growth not only boosts procedural volumes but also encourages competitive pricing and innovation, reinforcing Asia Pacific’s position as the fastest growing regional market for coronary and peripheral stents.

Asia Pacific Coronary and Peripheral Stents Market Country Insights

Based on country, the Asia Pacific coronary and peripheral stents Market is further segmented into China, Japan, South Korea, India, Australia, New Zealand, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Taiwan, Bangladesh, and Rest of Asia. China held the largest share in 2024.

China dominates the Asia Pacific coronary and peripheral stents market, emerging as both the largest and fastest growing country in the region. Its leadership is driven by a combination of large patient base, government-backed healthcare reforms, and strong domestic manufacturing presence. Local companies such as Lepu Medical and MicroPort compete alongside global leaders like Abbott, Boston Scientific, and Medtronic, creating a highly competitive environment that drives innovation and affordability. Centralized procurement policies emphasize cost-effective solutions, accelerating adoption of drug‑eluting stents, while peripheral stent usage is expanding in response to rising cases of peripheral artery disease. China’s investment in hospital infrastructure, physician training, and R&D ensures continuous growth, with urban centers leading in procedural volumes and rural areas gradually gaining access. The country’s dual strength in manufacturing and clinical adoption positions it as the benchmark for Asia Pacific, making China not only the dominant market but also the fastest advancing in technology adoption and patient reach.

Asia Pacific Coronary and Peripheral Stents Market Company Profiles

Medtronic, Boston Scientific Corporation, Abbott, B. Braun SE, TERUMO CORPORATION, Teleflex Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Cook Medical, Meril Life Sciences and Translumina are among the key players operating in the market. These players adopt strategies such as expansion, product innovation, and mergers and acquisitions to stay competitive in the market and offer innovative products to their consumers.

Asia Pacific Coronary and Peripheral Stents Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

• Primary Research

Business Market Insights conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:

• Refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

Asia Pacific Coronary and Peripheral Stents Key Sources Referred:

• The World Bank
• World Health Organization (WHO)
• Center for Disease Control and Prevention (CDC)
• European Society of Cardiology
• American College of Cardiology
• American Heart Association
• Asian Pacific Society of Interventional Cardiology
• Company website
• Company annual reports
• Company investor presentations